**Table 2.** Summary of clinically available type I collagen-based injectable formulations.







### **6. Clinical Efficacy of Collagen-Based Injectable Implants**

Collagen-based formulations are mainly used for the treatment of several kind of diseases belonging mainly to the musculoskeletal (i.e., hip or knee osteoarthritis [112,131,133,140,142,144,182], sprained knee pain [143], injured cartilage [138,141], piriformis syndrome [136], ankle and hindfoot arthritis [103] or fusion [100,106–109], lumbar spinal fusion [99], myofascial pain syndrome [130,137], chronic pain [132], acute lumbar spine pain [134], partial-thickness rotator cuff tears [141,146,183], plantar fasciitis [184], calcific supraspinatus tendinitis [145], pain [130,132,134,137]), urogenital (i.e., urinary incontinence [122,124,125,185–189], neurogenic urinary incontinence [190], lichens sclerosus [165], intrinsic sphincter deficiency [191–193], post-prostatectomy incontinence [65,123,194–197], retrograde ejaculation [198]), gastrointestinal (i.e., glottic insufficiency [113,114,116,118,119,173,199–203], rectal fistula [153,154,156,157], fecal incontinence [69,115,155,204]), and integumental (i.e., nasolabial folds [2,67,76,86,87,96, 149,163,172,205–208], nasojugal folds [152], lip [2,77,95,148,169,172], cheek and temple area [172], glabellar groove [77], post-rhinoplasty dorsal irregularities [77,209], depressed acne scars [77,172,210] augmentation, post-burn hands malfunction [88] and vitiligo [164]) systems, as well as for non standard clinical applications (i.e., facial nerve rehabilitation after palsy [160,211], organ protection during thermal ablation [129], COVID-19 associated hyperinflammation [161,162] (NCT04517162), vitiligo [164], ovarian function after premature ovarian failure [212], the closure of artery aneurysms [128,213] and blood volume augmentation [127,214]) (Figure 2).

However, many manufacturers have chosen to not publish their findings but keep their data privately on file. Thus, no public clinical efficacy research results are available for many injectable solutions, meaning that the limited information available restricts the discussion on the efficacy and safety of collagen-based formulations for healthcare applications.

### *6.1. Integumental Apparatus*

Type I collagen is the main component of skin (85–90% type I collagen, 10–15% type III collagen). Fibrillar collagen types I, III, and V self-assemble into larger collagen fibers that form the dermis 3D network [215].

To improve the appearance of aged skin many non-invasive (i.e., topical formulations, oral supplements), minimally invasive (i.e., dermal fillers) and surgical treatments (i.e., blepharoplasty) were developed. Although a multitude of topical treatments are available for the improvement of aged skin appearance, these procedures appeared to have minimal ability to remodel dermal ECM [215]. However, collagen supplements originating from various animal sources such as marine, bovine, and porcine were revealed to be able to partially improve skin integrity. Thus, injectables became more popular for their immediate effect. As previously noted, several biomaterials (i.e., collagen, hyaluronic acid, calcium hydroxyl apatite, carboxy methyl cellulose, poly (methyl methacrylate), poly(L-lactic acid) were employed for the development of skin filler, each of which has some advantages and drawbacks.

Among them, collagen is the most promising for its low adverse effects rate and natural filling effect. The return to favor of collagen injectables for aesthetic medicine could be due to the acquired knowledge about chronological skin aging processes. Wrinkles formation is caused by collagen density decrease due to its turn-over slowingdown [215]. Its decreased synthesis and replacement rate causes matrix loss and thus skin collapse and loss of elasticity, which in turn leads to the appearance of wrinkles, folds, and facial contour changes, as masterfully described by Fisher et al. 2008 [215]. Due to this, several commercial collagen-based products are available and are used principally for facial contouring, such as for nasolabial folds [2,67,76,86,87,96,149,163,172,205–208], nasojugal folds [152], lip [2,77,95,148,169,172], cheek and temple area [172], glabellar groove [77], post-rhinoplasty dorsal irregularities [77,209], depressed acne scars [77,172, 210], augmentation [96,172].

1

Usually, collagen injectable formulations for antiaging treatments are supplied in the form of dry powder to be resuspended in a suitable buffer (e.g., NaCl 0.9%) or in liquid form in ready-to-use syringes with a final collagen concentration of 30–35 mg/mL. A total of 2–5 mL is injected to reach the desired effect. In particular, a volume of about 0.9–3.0 mL [67,86,95, 149,205–208] is injected in the first session, but because of collagen's rapid degradation, 1–3 touch-up treatments [67,87,96,149,206] of about 0.8–2.1 mL [67,149,206] are usually performed usually after 1–2 week from the first treatment [67,76,86,87,96,149,208] and more rarely after 1 [206] or 6 months [207].

**Figure 2.** Main collagen-based injectables applications for the treatment of several kind of diseases belonging to the integumental, musculoskeletal, urogenital, gastro-intestinal apparatus, besides for non-standard clinical applications.

An improvement of the Crows' feet severity, Facial Volume Loss Scale (FVLS), and Wrinkle Severity Rating Scale (WSRS) of about 1 point was registered almost always after 6–8 months [86,163]. Accordingly, the improvement of the Global Aesthetic Improvement Scale (GAIS), Merz Aesthetic Scale (MAS) after 12 weeks of at least 1 point was registered in

another study [67]. The maximum WSRS improvement of about 0.5–1.0 point was usually reached after 3 months [96,205,206]. However, the WSRS and GAIS score were reduced by about 0.5–1.0 and 1.0–1.5 points respectively after 12–24 months, confirming the biodegradability of collagen fillers and therefore the need to resort to multiple injections to maintain the desired effect [87,96]. Indeed, based on overall Subject Global Evaluation scores, patients reported 96% aesthetic improvement at the week-3 follow-up visit, a value that decreased to 60% at month-3 and to 15% at month-13 post–last treatment visits [205]. However, collagen persistence has been successfully improved by about 2 points of the WSRS scale after 6 months and prolonged with the use of crosslinked collagen (Dermicol-P35) up to 1 year with 1 touch-up after 1 week without immediate or delayed positive hypersensitivity reactions [149,208]. Collagen filler injected volume or its animal extraction may not be the influencing factor of collagen efficacy or side effects. Several studies reported how injected volume did not differ significantly between porcine collagen formulation (i.e., 2.03–2.11 mL for nasolabial fold, 0.90 mL for lip) and bovine collagen formulation (i.e., 1.8–2.1 mL for nasolabial fold, 0.85 mL for lip) nor were statistically significant differences registered in WSRS and GAIS score improvement, patients' satisfaction and adverse events [86,87,95]. Collagen fillers (Dermicol-P35, Artecoll®, Cymetra) demonstrated their effectiveness also in cases of depressed acne scars since they allowed to reach a high degree of correction, with no adverse events and high patient satisfaction level [77,172,210]. Although the acne scars were not completely removed, their appearance was greatly improved [210].

Collagen filler is generally considered safe. As shown in Table 3, fillers were well tolerated and there were no serious adverse reactions [67,87,96,163,216]. Indeed, serious adverse events that were not injection site related usually not occur [67]. However, all injection site reactions were mild to moderate in severity and resolved in 1–2 weeks without sequalae [2,86], except for some rare cases. Usually, 80% of participants had at least 1 injection site reaction after the initial injection [67]. Light/moderate bruises appear on the injection points that totally disappeared within 5–10 days [163]. Only one severe bruising was reported after 1-week follow-up and resolved after 4 weeks [67]. A case of mild induration after 4 weeks resolved in 6–12 weeks [67].

As previously mentioned, with the spreading idea of regenerating lost tissues rather than repairing them, collagen formulations started to be employed not only for aesthetic medicine but also for regenerative medicine. Only recently, collagen fillers started to be used for the treatment of other integumentary apparatus diseases such as the post-burn hands malfunction [88] and vitiligo [164]. Indeed, the potential of a collagen-glycosaminoglycans matrix (INTEGRATM Flowable Wound Matrix) has been investigated for post-burn hands treatment with the idea that its composition was supposed to have the potential to rebuild the lost or injured deep dermal structure and enable soft tissue augmentation [88]. The work of Hirche et al. was the first pilot study using percutaneous injectable collagenglycosaminoglycans matrix for post-burn dermal augmentation safety and efficiency, and active range of motion (AROM), disabilities of the arm, shoulder and hand (DASH) score, Vancouver scar scale (VSS) score and scar quality improvement were registered after 6 months [88]. Despite the encouraging results, further studies on the formulation's long-term efficacy on a higher number of patients are necessary in order to evaluate the possible quality of life and grip strength that appeared to not be changed after 6 observation months [88]. More recently, collagen injections were proposed also for unresolved diseases such as vitiligo. Although a variety of treatments for the re-pigmentation of vitiligo lesions are available (e.g., platelet-rich plasma injections, UV-phototherapy), none of them effectively promote complete and long-lasting re-pigmentation. Thus, the potential synergistic effect of intradermal collagen injections (Linerase®) in combination with UVphototherapy was investigated and 70% re-pigmentation occurred after six sessions with mild-to-moderate pain and no adverse events [164]. Moreover, no relapses were reported after one year [164].

*Polymers* **2023**, *15*, 1020



### *6.2. Musculoskeletal Apparatus*

Aging leads not only to skin texture loss but also to a progressive and gradual reduction of all human capabilities. The loss of muscle or osteochondral mass with advancing age is the major public health problem for the elderly population. Thus, musculoskeletal apparatus-related medical treatments and costs increase with population age (numbers over 50 years). Among invasive and non-invasive currently available treatments, collagen injections are revealed to be quite effective for the treatment of several musculoskeletal diseases such as hip [131] or knee osteoarthritis [112,133,140,142,144,182], sprained knee pain [143], injured cartilage [138,141], piriformis syndrome [134], ankle and hindfoot arthritis [103] or fusion [100,106–109], lumbar spinal fusion [99], myofascial pain syndrome [130,137], chronic pain [132], acute lumbar spine pain [134] and in partial-thickness rotator cuff tears [141,144,183], plantar fasciitis [184], and calcific supraspinatus tendinitis [145] and pain [130,132,134,137].

Osteoarthritis is an inflammatory degenerative disease characterized by the progressive damage of articular cartilage and underlying bone that predominantly affects hip and knee [218]. Interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6 seem to be the main proinflammatory cytokines involved in the pathophysiology of osteoarthritis, even though others, including IL-15, IL-18, IL-21, leukemia inhibitory factor (LIF), and chemokines are implicated [182,219]. The expression of these inflammation mediators in turn activates the cartilage-degrading enzymes, that are matrix metalloproteinases (MMPs) and A disintegrin metalloproteinase with thrombospondin motifs (ADAMTS) [112,219], that progressively degrade the ECM, including collagen. From this observation, several studies were performed to prove the hypothesis that an exogenous administration of collagen may be beneficial to osteoarthritis damaged cartilage and bone.

Indeed, a total of 12 mL of collagen and polyvinylpyrrolidone based formulation (Fibroquel®) affected the values of the Lequesne index (LKI) by <sup>−</sup>51%, Western Ontario and McMaster University Index (WOMAC) pain subscale by –51%, WOMAC stiffness subscale by −49%, WOMAC disability subscale by −42%, and the use of analgesics by –83% after 6 months [182]. Moreover, pro-inflammatory cytokine expression was lowered in patients under collagen treatment compared with placebo [192]. Injections of collagen, arnica and hypericum (MD-Knee® and MD-Muscle®) brought a significant reduction of Visual Analogue Scale (VAS) pain at rest with a decrease of the average score for pain during movement of more than two-fold after 12 weeks [133]. Similar results were obtained by Martin et al. who found a LKI and VAS significant improvement 6 months after five weekly injections (a total of 20 mL) of MD-Knee® [144]. More recently, analogous clinical outcomes were obtained with pure collagen formulations, with a reduced number of injections. Indeed, three injections of a hydrolyzed collagen suspension (a total of 6 mL of CHondroGrid®) significantly reduced VAS, LKI, and WOMAC scores [112], by up to about 50% [142].

Because of the avascular, aneural, and immunoprivileged nature of hyaline cartilage, the regenerative potential of cartilage after injury is limited. In this circumstance, collagen injections revealed to be a promising modality for single-stage cartilage repair: collagen augmented chondrogenesis by 50% filling of the microfractures with CartiFill®. This showed a superior VAS improvement rate analysis and a superior filling rate in the cartilage tissues as well as integration with the surrounding tissues 24 months postoperatively compared with that achieved only with microfracture [139].

Peri-articular collagen injections (MD-Knee® and MD-Matrix®) twice/week for 3 consecutive weeks revealed to be effective also for the treatment of sprained knee pain, with a rapid recovery and an excellent control of breakthrough pain without the use of antiinflammatory drugs [143].

Thus, all clinical outcomes confirmed the benefits in collagen use and allowed to define intra-articular collagen injection as inflammation down-modulator and cartilage regenerator 'biodrug' [182]. Collagen can effectively promote repair processes of the cartilage matrix, interrupting the degenerative process and articular damage, which causes

inflammation and pain [144]. The administration of type I collagen after arthroscopic lavage is safe and effective and induced systemic inflammation downregulation [182]. Adverse events are rare, most frequently including site pain that lasts at most 24 h [131,182]. No aseptic acute arthritis, infections after injection or any other complication have ever been registered [112,131,182]. Taking into account that osteoarthritis is the most common form of musculoskeletal disorder with a prevalence of 23% of over 40 people and an annual incidence of 203 per 10,000 person/year [220], it is easy to understand how it has high economic costs and a devastating impact on patient quality of life. The above-mentioned recent studies showed how the benefits associated with the use of collagen make it a very promising non-invasive solution that has begun to find its place among conventional therapies (i.e., corticosteroids, polynucleotides, platelet-rich plasma, hyaluronic acid intra-articular injections). Although today collagen injections are still less popular than hyaluronan, they exert a similar clinical effect, besides being equally well tolerated both locally and at a systemic level, confirming the material non-inferiority [144]. The reduced cost of collagenbased formulations compared to hyaluronic acid-based formulations could bring to the attainment of the intra-articular therapy to a broad range of the population, resulting in the reduction of social cost due to working days lost and caregivers' time off work [144].

Osteochondral disorders are followed by less common but equally disabling muscular and tendon pain. Inflammatory or degenerative process, fracture, radicular syndrome, or nonspecific syndrome are causes of chronic musculoskeletal pain, which is the most common health complaint, with significant social and economic consequences [132,134]. The incidence of musculoskeletal pain increases with age and strongly affects the quality of life of a growing number of affected people [137]. Current medical procedures include conservative methods (i.e., rehabilitation, medications), minimally invasive interventions (e.g., acupuncture) or surgical treatment. However, the huge risk of gastrotoxicity, hepatotoxicity, cardiotoxicity and nephrotoxicity, after long-term and/or high doses of common nonsteroidal anti-inflammatory drugs, pushed researchers toward the investigation of safer options [134]. In this circumstance, the subcutaneous/intramuscular administration of collagen containing products (MD-Lumbar MD®, MD-Muscle®, MD-Neural®) represented a new concept in the treatment of pain, that is based on the strengthening the collagen matrix underlying the musculoskeletal system structures and on the analgesic effects of these products. Although few published data are available, it is clear that collagen-based injections represent a safer treatment option with no adverse events, 54–60% pain relief [130,132], good tolerability [134], and comparable or better efficacy with the standard treatments [130,134].

Only recently the efficacy of collagen injections (RegenSeal®, MD-Shoulder®, MD-Muscle®) for the treatment of tendon tear have been clinically investigated [141,183,184]. The first prospective, randomized clinical trial has been conducted by Kim et al. in 2020 and reported rotator cuff functional outcomes improvement and a decreased tear size in 37% of patients with a single collagen injection (0.5–1.0 mL) [141]. A case study confirmed how multiple intratendinous weekly injections of 2 mL of collagen are able to reduce the partial-thickness tear in three months and to completely heal tendon tear in 18 months, which in addition appeared quite regular and isoechoic [183]. Collagen injections were thus found to be effective to decrease tear size (50–77% complete recovery), pain, increase functional shoulder score and delay tear progression in partial-thickness rotator cuff tears [141,145,146,183]. The precise mechanism of tendon healing after injection of collagen is still unknown. However, two in vivo studies on rabbits proved that injections of collagen in the tissue during the ECM remodeling phase led to better tendon healing and earlier progression to the remodeling phase [141,221,222]. Both histological and biomechanical studies of type I collagen implants facilitated continuity of injured tendons, decreased peritendinous adhesion, and improved muscle activity in Achilles tendons of rabbits [221,222]. Despite their low efficacy rate and their limited use, collagen injections would be more advantageous than traditional surgery for their cost-effectiveness, easy performance and less time-consuming nature.

### *6.3. Urogenital System*

Collagen injections have been revealed to be a minimally invasive and quite effective solution for specific urogenital system diseases such as stress urinary incontinence [122,124,125,185–189], neurogenic urinary incontinence [190], lichens sclerosus [165], intrinsic sphincter deficiency [191–193], post-prostatectomy incontinence [65,123,194–197], retrograde ejaculation [198] and ovarian function after premature ovarian failure [212].

Stress urinary incontinence affects 10–30% of women above 50 years of age [185]. To solve this common issue, in addition to surgical practices (i.e., retropubic bladder neck suspension or slings), biomaterials injections (i.e., teflon, fat, silicone, collagen) have been performed to increase urethral strength and avoid urinary leak. Among them, collagen (Contigen®, Linerase®) has remained the most promising. In a study of Martins et al., either cure or improvement was achieved in 86% of women, with a registered leak pressure increase and reduction in urinary protector use and urine leakage volume [185]. In another study, 48% were totally dry and 31% were socially continent after 2 months [187]. However, because of collagen absorption, stress urinary incontinence recurrence occurred in 41% of patients who achieved continence after 7–8 months [187]. Collagen reportedly degraded completely within 10–19 weeks, although magnetic resonance imaging of the urethra showed the persistence of the implant for as long as 22 months after injection [196]. Thus, repeated injections (2–5) may be necessary [187,188,190]. Hence, reinjections were performed, with a 42% regain of continence, giving a long-term success rate of 58–60% [187]. Totally favorable results, including improvement (40%) and cure (30%), were also recorded for up to 4 years [124]. However, it should be mentioned that elderly patients should be counseled that approximately 40% will experience recurrent leakage, which may not resolve with reinjection [187]. Conversely, Gorton et al. reported the absence of correlation between long-term success and the number of previous operations, body mass index, age, number or total volume of collagen injections [125].

Men's post-prostatectomy incontinence incidence ranges from 2% to 87% [123]. The most commonly performed surgical procedures include the insertion of an artificial urinary sphincter or of injectable bulking agents. In this case, collagen (Contigen®) is the most commonly used and several works reported how 3–4 collagen injections led 8–20% of patients to dryness and 38–39% to significant improvement [123,194]. Treatment was found to be pad related. The highest success rate was reached in patients that fewer than 6 pads per day (72%) a value that lowers up to 29% for patients using more than 6 pads per day [123]. Moreover, in cases of radiation therapy or bladder neck incision after a radical prostatectomy, the success rate is even lower [123]. The success rate of collagen injection strongly decreased in the treatment of urinary incontinence in children with neurogenic bladder dysfunction secondary to myelomeningocele. In this case, only 15% improved and 5% were completely dry [190]. Additionally, the initial improvement in the first 2 months after injection deteriorated thereafter in 80% of children [190]. The first severe case was registered in 2006, when three years after a single sub ureteral collagen injection for the treatment of bilateral vesicoureteral reflux in a 1 year of age girl, hydronephrosis with ureteral stenosis with a knotty sclerosis and a histiocytic and granulomatous reaction occurred and required ureteral reimplantation [223]. Despite the widespread and long-term application of collagen for the treatment of stress urinary incontinence, treatment-related morbidity was minimal. Urinary tract infections occurred in 6% to 25% of cases while transient hematuria and hypersensitivity were occasionally reported [124,125]. No implant migration, nor seroconversion to antibodies that cross-reacted with human collagen, nor symptoms were even registered [123]. However, patients who have required a penile clamp and experienced continuous leakage or those who have undergone transurethral incision of a bladder neck contracture are unlikely to respond well to collagen injection therapy [194].

Recently, collagen injections (Linerase®) have been proposed for the treatment of male genital *lichen sclerosus* and retrograde ejaculation. In the case of lichens sclerosus, it revealed to be safe and effective in 10 days and for up to 12 months [165]. Likewise, two injections of 6 mL of collagen (one per year) were revealed to be effective and complication free in cases of retrograde ejaculation [198].

Collagen-based injections were also found to be effective for the treatment of premature ovarian failure [212]. Indeed, umbilical cord mesenchymal stem cells loaded collagen formulation was found to be able to rescue overall ovarian function, evidenced by elevated estradiol concentrations, improved follicular development, and increased number of antral follicles [212]. Moreover, successful clinical pregnancy was achieved after the transplantation of the cell loaded collagen gel [212].

Thus, collagen injections seemed to be a simple, least morbid, cost-effective, and effective treatment for disease affecting the urinary apparatus, with low failure rates [123].

### *6.4. Gastrointestinal Apparatus*

Injectable collagen has been shown to be effective in the management of gastrointestinal apparatus diseases such as glottic insufficiency [113,114,116–119,173,199–203], rectal fistula [153,154,156,157] and fecal incontinence [115,155,204].

Glottic dysfunctions due to glottic gap, atrophy, paresis, bowing, paralysis and scarring result in voice absence or alteration. The gold standard for the treatment of vocal fold disfunctions is represented by medialization laryngoplasty or arytenoid adduction, surgical treatments that could significantly improve glottal adduction and phonation. Recently, to reach a better postoperative voice in the long term, biomaterials injection (i.e., autologous fat, silicone, collagen, hyaluronic acid, carboxymethylcellulose) [116,224,225] has been additionally performed. However, autograft represent the known advantages of a double surgery, but means double surgery time and costs. Instead, xenografts are an attractive alternative for supplementing arytenoid adduction, because of their noninvasiveness, ready availability, and possibility to be performed under local anesthesia. Among them, collagen injectable formulations proved to be effective for vocal fold management. Patients treated with 1–2 mL of selected collagen injectable formulations (Koken®, AlloDerm®, Zyplast®) showed at least some improvement in vocal function after the treatment, according to the Grade, Roughness, Breathiness, Asthenia, Strain (GRBAS) scale, Maximum phonation time, Mean flow rate, Relative glottal area. In particular, perceptual and objective voice quality improvement (less weak and breathy) was registered, with an increase of the mean maximum phonation time from around 8–11 s to 13–15 s, and a reduction of the mean flow rate from 322–564 mL/s to 223–385 mL/s and of the glottal gap [113,114,200], for at least up to 2 years after operation [114]. Thus, from the moment in which the safety and efficacy of collagen injections for the treatment of the vocal cords was affirmed by Ford and Bless in 1993 [202], the injection of heterologous material started to be even more required, given the positive feedback and long-term results [118]. Although collagen injections were quite effective, and serious adverse events were rare [113,114,117,202], documented complications included local abscess, migration of the implant, hypersensitivity reactions, stiffening, fusiform collagen mass, nodules [116,173] principally related to the procedure and injection site [113]. Indeed, if properly injected, the complication rate after collagen injection would decrease [200].

Anal fistula is a tunnel that connects an infected cavity in the anus, to an opening on the skin. Usually, fistulas are surgically removed by fistulotomy, which is the gold standard procedure (37–98% success rate). However, complex fistula fistulotomy may result in variable degrees of anal sphincter apparatus impairment. Several alternative treatments were proposed and among them a trans anal rectal advancement flap represents the most effective treatment for complex anal fistulas allowing the successful closure of the internal opening. However, the recurrence rate is approximately 30% [157]. The interest in biomaterials use increased for their simple and repeatable application, preservation of sphincter integrity, and minimal patient's discomfort [157]. Among biomaterials, fibrin glue and collagen injections were proposed. Fibrin glue was soon abandoned for its high rates of recurrences. Conversely, collagen injections (Permacol®) were revealed to be effective to treat anal fistula. In particular, no complications occurred and complete healing was reached after 3–15 months upon surgery [156–158]. The treatment success rate varies among studies, with a 56% of success rate at 12 months of follow up in a more recent study [156]. However, it should be mentioned that patients' characteristics play a key role in the healing rate since a significant correlation with age was registered by Giordano et al. [156], with an increased chance of healing as age increased. While some authors confirmed the complete safety of the procedure and of the collagen injections [153,154,157,158], others registered middle-serious adverse events, including abscess (3%), bleeding (3%) and pain (7%) [156]. Although reports suggest that collagen injections are quite safe, minimally invasive, healing promoters for the sphincter-preserving procedure, and well tolerated by patients, further studies are needed for confirming their effectiveness in the treatment for complex anal fistulas.

Similarly, collagen injections were revealed to be quite effective for the treatment of fecal incontinence [115,155]. As reported by Stojkovic et al., after 2 months 5% of patients were completely continent, 58% had an improved incontinence score and 37% had no change or a worse score [115]. Healing was discovered to be strictly dependent on the incontinence etiology: a significant improvement of the incontinence score was indeed registered in case of idiopathic fecal incontinence and in older people while no improvements were observed in case of neuropathic or traumatic incontinence [115]. Despite the partial positive 1–2 years positive follow up, the disadvantage of collagen as filler agent is that degradation occurs over a period of 12–30 months [115] that obliges at least one repeat injection.

### *6.5. Others*

New experimentations using collagen-based formulations were performed for nonstandard clinical applications such as facial nerve rehabilitation after palsy [160,211], organ protection during thermal ablation [129], COVID-19 related hyperinflammation [161,162] (NCT04517162), artery aneurysms closure [128,213], blood volume augmentation [127,214] and the treatment of chronic ischemic heart diseases [226].

Given the absence of experiences with collagen-based injections in the field of facial palsy rehabilitation, the aim of a recent pilot randomized study was to test the shortterm effectiveness of a collagen-based treatment (MD Neural®, MD Matrix® and MD Muscle®) on patients complaining of long-standing facial nerve axonotmesis with the possible expectation of collagen redirecting and guiding reinnervation/reorganization processes [160,211]. Although the recovery outcomes are difficult to interpret because of the presence of several confounding factors (i.e., palsy etiology, time from disease onset, patients' age, association of medical treatment), a significant improvement of both electrophysiological and questionnaire scores in the duration of voluntary activity was found in patients treated with in situ collagen injections [160,211].

Another recent application field for collagen-based injectable formulations is in the surrounding organ protection during tumor thermal ablation [129]. Organ protection is usually performed by using fluids (e.g., dextrose) or gas (e.g., CO2) displacement but because of their physical properties they distribute freely in the injection site and decrease the durability of separation. The injection of a highly viscous fibrillar collagen (Helitene®) focally interposed between the liver and adjacent structures prior to hepatic microwave ablation made the organ separation durable, low cost, well tolerated, facilitated hemostasis and healing besides making thermal ablation technically successful without complication [129].

A collagen-based injectable formulation was found to be a potential drug in the treatment of symptomatic COVID-19 patients for its immunomodulatory properties, in relation to IL-1β, IL-8, TNF-α, TNF-β1, IL-17, cyclooxygenase 1 (Cox-1), endothelial leucocyte adhesion molecule 1 (ELAM-1), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1) downregulation, tissues fibrosis reduction, and IL-10 and T cells upregulation. Intramuscular injection of collagen (Fibroquel®) was able to significantly decrease the interferon gamma-induced protein 10 (IP-10), IL-8, macrophage colony-stimulating factor (M-CSF), high-sensitivity C-reactive protein (hsCRP), D-dimer

and lactate dehydrogenase (LDH) levels, in the first week of treatment [162] (NCT04517162). Moreover, collagen injections were associated with better oxygen saturation values and shortened symptom duration, extubation and reduced inflammation when compared to placebo [161,162] (NCT04517162). Thus, collagen-based injections were considered safe and well-tolerated and did not induce liver damage, infections, impairment of hematopoiesis or blood alterations [161,162] (NCT04517162).

Interestingly, collagen intravenous injections (Gelaspan®, Gelofusione®) were successful for blood volume expansion in cases of dehydration, illness, trauma or severe sepsis/septic shock related surgery and were found to be more effective in achieving hemodynamic stability in critically ill patients compared to standard plasma volume replacement products, with no side effects [127,214].

In cases of complications due to percutaneous transfemoral catheter procedures, vascular surgery is necessary after the failure of the ultrasound-guided compression repair attempt [128]. A less invasive method to percutaneously close a femoral artery pseudoaneurysm was found by injecting collagen and inducing clotting within the aneurysm, with a 98% success rate [128]. The hemostatic power of collagen is due to the fact that the collagen hydrogel forms an 3D network which triggers the hemostatic cascade (i.e., platelet aggregation, adherence, and activation) [213]. Moreover, upon contact with blood, the collagen expands its physical mass resulting in mechanical occlusion of the vessel puncture site and tissue tract [213].

Despite all the functional improvements that collagen is able to support in several diseases, neither improvement nor adverse events were observed in patients with chronic ischemic heart disease treated with mesenchymal stromal cells in a collagen gel vehicle compared with control patients and patients treated with mesenchymal stromal cells alone [226].

Thus, as emerged in this section, collagen-based injectable formulations can be very useful in the treatment of unresolved issues and open the way for new solutions and less invasive approaches. Based on this evidence, even more research has been performed and accordingly, even more clinical studies have been planned. Hence, besides the discussed clinical outcomes, several clinical studies aiming at improving functional recovery of liver in cases of decompensate cirrhosis (NCT02786017), brain in cases of intracranial hematoma (NCT02767817), erectile function in men with type I or II diabetes mellitus (NCT02745808), blood volume during surgery (NCT02808325, NCT01515397) and fluid retention in cases of breast cancer (NCT04637308) are ongoing (Table 4).


**Table 4.** New applications of collagen based injectable formulations.

### **7. Adverse Reactions to Collagen-Based Injectable Implants**

All types of fillers may trigger an early tissue response to the injected material. Regardless of the filler material, frequently reported side effects are bruising, redness, swelling, induration, erythema pain, tenderness, itching and, in the most severe cases, violaceous plaque and granulomas [227–229]. These side effects are usually mild and transient and resolve spontaneously after a short time. Only a few cases of severe and permanent complications have been registered.

Although compared with other injectables collagen-based formulations have many advantages, it does not mean that they are absolutely safe. Indeed, severe and nonsevere adverse reactions to collagen treatments may occur. To the best of our knowledge, based on harvested and available data on adverse reactions registered after collagenbased commercial product applications (Table 5), severe adverse events accounted for 8.2% (211 cases on 2587 patients), while mild adverse events accounted for about 5.3% (137 cases on 2587 patients) of those receiving the treatment.

With a focus on collagen extraction sources, it emerged that severe adverse events accounted for 12.1% (211 cases on 1742 patients) and mild events for 3.8% (67 on 1742 patients) when bovine collagen was used. In particular, severe adverse events were addressed to the use of one collagen-based product that was Augment®, an injectable formulation composed of bovine collagen, β-tricalcium phosphate and recombinant human platelet-derived growth factor-BB [102] (NCT01305356, NCT00583375). Leaving aside the Augment® severe adverse reactions (211 on 1742 procedures), the other analyzed bovine collagen-based products (i.e., ChondroGrid, Atelocell, Zyderm, Zyplast, Contigen, Gelofusine, Flowable wound matrix and Helitene) were not associated with such issues [88,113,114,116,118,127,129,142,187,188,190,214,230] (NCT02808325, NCT04637308, NCT02715466, NCT01515397, NCT02631356, NCT00868062). Since bovine collagen appeared to be safe, these events could be ascribable to other Augment components, without certainty. As regards mild adverse reactions, they were registered only when using Augment, Chondrogrid or Zyderm [101,106,118,142].

Porcine derived collagen-based products (i.e., Cartifil, Cartizol, Fibroquel, Permacol and MD products) revealed to not trigger severe adverse events (no cases on 751 procedures) and to be responsible for the 9.2% of mild adverse events (69 cases on 751 procedures) [131–136,138,140,141,143,145,146,153–157,160–162,182,204] (NCT02539030, NCT02539095, NCT04019782, NCT03323567, NCT02539082, NCT01528995, NCT04517162, NCT04353908). Mild adverse events could be due both to collagen type or to other components (i.e., glucose, CaCl, amino acids, vitamin B, fibrin glue for Cartifil/Cartizol; polyvinylpyrrolidone for Fibroquel) or to the injection procedure. However, data were not enough to identify the causes. Definitely though, the low mild adverse events rate of the MD product could be clearly ascribable to the presence of other bioactive compounds (such as calcium phosphate, rhododendron, arnica, hamemelis, silicon, iris, viola, cimifuga, citric acid, nicotinamide, hypericum, drosera, citrullus, ascorbic acid, magnesium gluconate, pyridoxine chlorhydrate, riboflavin, thiamine chlorhydrate) that had a strong impact on patients' post intervention events. As regards Permacol, since it is not characterized by the presence of other components, adverse events triggered by its use could be attributed to collagen type, to the injection procedure, to the disease or to the patient specific response. In this case, available data do not allow clearly attribution of responsibility. However, mild adverse event usually resolved spontaneously or required minimal, not invasive intervention [131,140,141,156,160,162,204] (NCT04353908, NCT04517162, NCT01528995, NCT02539030).

The third most used collagen type Is equine derived collagen, whose use is very recent and thus limited compared to bovine and porcine derived injectable products. Indeed, it has been reported to be used (i.e., Linerase, Savecoll-E) only on 94 patients, with no adverse events and only one registered mild reaction (1.1%) [60,164–166]. Thus, although this percentage seems to be very low compared to other products, the limited number of executed procedures with equine collagen prevented the assessment of this collagen type

as safer. This consideration could be applied also for human collagen derived products (i.e., Cymetra, Dermologen) for which two severe and zero mild adverse events were registered on the only patients [173,202]. However, these data and these considerations are only indicative because not all studies reported participant number and adverse event occurrence.

As regards aesthetic applications, collagen injectables are generally considered as safe because serious adverse events that were not injection site related usually not occur [67]. Indeed, severe adverse events rate accounted for 0.1% of the total (2 cases on 2063 patients). In particular, severe adverse events occurred only when using porcine derived collagen Dermicol-P35 (with ribose as crosslinker) and RPC Pure Collagen (with ethylenediamine tetraacetic acid) [67,147]. However, two cases occurring on 780 injections were not enough to relate the adverse events to collagen type or other components. Contrarily, non-severe adverse reactions always occur (Table 3) and accounted for 28% (577 cases on 2063 patients). They may be categorized into early and late reaction [16,231]. Usually, injection site reactions were mild to moderate in severity and resolved in 1–2 weeks without sequelae [2,86], except for some rare cases. About 80% of participants had at least 1 injection site reaction after the initial injection [67]. This kind of adverse reaction is localized and may be associated with transient systemic symptoms on rare occasions [232]. Early complications occur immediately up to several days after treatment and completely auto-resolve in a few months, without treatment [217,227,229]. They can be divided into non-hypersensitive and hypersensitive reactions. Non-hypersensitive reactions, which can occur with any filler, include local injection site reactions (i.e., erythema, edema, pain, tenderness, bruising, itching), discoloration (i.e., redness, whiteness, or hyperpigmentation), infections (i.e., herpes virus reactivation or bacterial contamination), skin necrosis (vascular occlusion), and misplacement [231]. Hypersensitive reactions are due to the material and depend on patient immune system reactivity and hypersensitivity. Late complications occur after 2–12 months and consist in foreign body granulomatous reaction, granulomas, and abscess formation [231]. Among non-severe adverse events, pain (13.9%), nodule (11.0%), bruises (11.1%), edema (11.3%), erythema (17.8%), itching (5.8%), swelling (6.0%), tenderness (3.0%), lumpiness (1.4%), induration (12.0%), discoloration (5.3%) were the most common. Very rare were cold sores, infections, blistering, papules, and hemorrhages (>0.5%). Contrary to what might be expected, allergic reactions occurred only in 0.1% of cases.

In terms of collagen extraction source, bovine (48%) and porcine (38%) derived formulations were the most used, followed by human (11%) and equine derived (4%). Accordingly, Dermicol-P35 and Zyplast were the most used products, followed by Therafil, Artecol, Koken, Isolagen therapy, CosmoPlast, Nithya, RPC Pure-Collagen, Permacol, Sunmax FacialGain, and CosmoDerm. Non severe events were registered to happen with all collagen types, except for equine derived collagen-based formulations. Indeed, bovine and swine derived collagen-based formulations triggered 12.5% and 11.8% non-severe events (257 and 244 cases on 2063 injections, respectively), followed by human derived with about 3.7% (76 cases on 2063 injections). Equine collagen injectables were revealed to be adverse events free but it should be taken into account that reported data were referred to only one study performed on 72 people [163]. Thus, Nithya, RPC Pure Collagen and Artecol reported no adverse events [67,77,163]. The non-severe adverse events rate was reported to be of 39.2% for Dermicol-P35 (213 cases on 544 injections) [2,147–149,207,209,210] (NCT00891774, NCT00929071, NCT00911872), 94.7% for Permacol (18 cases on 19 injections) [95], while for the others the rate was about 7–36%. In particular, it was 32.8% for Zyplast (13/187 injections) [96] (NCT00876265), 20.2% for Koken (23/114 injections) [87], 29.1% for the Isolagen therapy (32/110 injections) (NCT00655356), 36.4% for Cosmoplast (43/118 injections) [205,206] (NCT00444210, NCT00444353), 33.3% for Cosmoderm (1/3 injections) [217] (NCT01212809) and 7% for Therafil, (13/187 injections) [87] (NCT01060943). In this case, the relatively low number of executed procedures prevented the assessment of product safety profiles and their comparison.

Although non-severe adverse reactions are neither life nor health threatening and thus are not of medical significance, they are cosmetically unacceptable. Nowadays, several tricks and improvements of the injection techniques have been made in order to avoid reactions caused by materials and procedures as much as possible [233]. Hypersensitive reactions are historically defined as the most common. Although it is rare (3% of the world population), some individuals develop allergic reactions to injected products when the body responds with an exaggerated immune response to a foreign substance. Allergic reactions generally occur within minutes of exposure, but delayed hypersensitivity can occur several months or years after injection [9]. Allergy to bovine derived collagen is genetically regulated by the lack of the HLA-DR4 antigen [234]. To avoid allergic reaction, skin testing now is mandatory. However, despite skin testing, hypersensitivity can occur in 1–6% of single skin test negative patients and in about 0.5% of double skin test negative patients [16,227–229]. Thus, a double skin testing is suggested before soft tissue augmentation [228,235]. Although double skin testing does not eliminate all adverse events, most of them were avoided because the great majority of adverse reactions occurred on the first injection session after a single skin test [232]. Collagen antigenicity is related to its molecular structure and is linked to its antigenic determinants that are located on the triple helix (i.e., dependent on the helix conformation), the polypeptide sequence (i.e., independent of the helices organization) and terminal (i.e., telopeptides) dependent [71,236–238]. However, it must be underlined that while collagen antigenicity has been attributed mostly to the terminal telopeptides, the location of the major antigenic sites depends on the specific donor/recipient species pair [71]. Alternatively, human collagen-based fillers offer a solution for their theoretical zero risk of allergic reaction. Nevertheless, erythema and hypersensitivity to human collagen was registered [217].

Foreign body granulomatous reaction and granulomas occurred in 0.01% of cases after 6–9 months after the treatment [231]. However, it must be taken into account that most of this kind of complication occurred with Artecoll®/Artefill®, probably due to the reaction to the poly(methyl methacrylate) microspheres rather than the collagenous component. However, the late adverse reactions to poly(methyl methacrylate) microspheres together with bovine collagen may have increased the immune system response.

Apart from the selected collagen formulation, as with any surgical or minimally invasive procedure, the result obtained with the injection therapy heavily depends on proper patient selection, expertise in performing the procedure, adequate knowledge of facial or other site's anatomy, and use of specialized equipment [13,123]. Only recently, the development of adequate implantation protocols permitted re-evaluation of collagen-based injectable therapies as a minimally invasive and effective strategies for the treatment of different types of diseases. Indeed, as preparation and administration techniques have become increasingly standardized, the frequency of post-injection complications has also decreased. Moreover, the selection of the appropriate filler, which depends on patient factors, including degree of volume loss, disease, age, cost, preference, and surgical candidacy was revealed to be crucial for the implant success [1], underscoring the need for product-specific training. Regardless of materials safety, appropriate handling and adequate experience are mandatory for minimizing the risk of complications and achieving the desired effect. An accurate guide on how to avoid and treat dermal filler complications has been developed by Lemperle et al. [233].

Swelling and bruising, which usually resolves within 4–10 days [163], could be attenuated by icing the area prior to treatment or by avoiding aspirin-containing compounds and anticoagulants, nonsteroidal anti-inflammatory drugs, and various vitamin supplements (e.g., vitamin E, fish oils) for 7–10 days before the procedure [152,231]. Only one severe bruising was reported after 1-week follow-up and resolved after 4 weeks [67]. A case of mild induration after 4 weeks resolved in 6–12 weeks [67].

The gauge of the needle, that depends on both the viscosity of the filler and the size of the particle, directly greatly contributes to the extent of superficial trauma and infections. Larger needle size can lead to a larger epithelial tear and greater disruption of dermal structures, with subsequent capillary leakage, edema, inflammation and sometimes infections [9].

Infection and abscess formation are rare complication of collagen fillers and can occur early on or can be delayed for several weeks to months after injection [231]. Early infections could be prevented by cleaning the treatment area with an antiseptic agent (e.g., isopropyl alcohol, chlorhexidine) while late infections could be treated by broad-spectrum antibiotics or anti-viral prophylaxis [231]. Herpes was registered in 1 case on approximately 15,000 injections [168]. Abscess formation is also rare (4 out of 10,000 patients) and occurs between 7 days to 22 months after treatment and may persist for weeks and periodically recur for months [16].

The occurrence of complications is also dependent on the injection site. Sensitive areas, such as around the mouth or beneath a muscle, heighten the risks for unwanted side effects. A bluish discoloration is associated with vascular injury due to injection. Vascular interruption also heightens the risk for local necrosis. Skin necrosis from mechanical disruption or occlusion of the vascular supply can rarely occur (9 out of 100,000 patients) [16]. Iatrogenic blindness is a rare but possible risk caused by misplaced intravascular injection. The risk is correlated to the complex vascular anatomy of the face interconnecting the extracranial and intracranial vascular network [13]. This tragic complication occurs when the filler is wrongly injected in the ophthalmic artery. Nowadays, several precautions can be taken to avoid necrosis. When injecting, attention should be paid to avoiding arteries, to aspirate before injecting, to use low volumes of products over more sessions as opposed to using high volumes over one session and to use only products that are manufactured for more superficial placement [231]. Moreover, warm compresses, massage, and tapping on the area were revealed to facilitate vasodilation and blood flow [231].

Improper distribution of injected products can also lead to lumps and nodules postinjection, besides facial shape deformity and asymmetry [9]. Denton et al. reported that it is very important to massage the product immediately after placement to mold and smooth the contour [152]. In case of over-injected or under-injected areas, palpation and massage should be performed to evenly distribute the material [86].

*Polymers* **2023**, *15*, 1020

**Table 5.** Collagen injection specifications (number, volume and time), adverse events recurrence (severe and non-severe) and other details from most recent clinical trials on musculoskeletal, gastro-intestinal, urinary, circulatory apparatus and others from 2000 to 2022.


*Polymers* **2023**, *15*, 1020



### **8. Regulation**

Resorbable injectable soft tissue fillers can be classified as medical devices, medicinal products, or cosmetic products. Injectable formulations are defined as medical devices if their therapeutic effect comes from their intrinsic structure, because their physical, chemical, or mechanical effects are the primary mechanism of action for their therapeutic function. The addition of any cells or cell-stimulating therapeutics into the injectable medical device results in their classification as medicinal products and in the following of other regulations. Indeed, medicinal product regulations require a more thorough investigation of the biocompatibility and therapeutic effect before approval for clinical application. Although medicinal products would be more effective, the translational barriers and the time before patients can benefit from them strongly increase.

In the United States, resorbable injectable soft tissue fillers have long been classified as medical devices while in Europe, dermal fillers have been marketed as medical devices, medicinal products, or cosmetics until now. However, with the entry into force of the new Medical Device Regulation (MDR) 2017/745 on 26 May 2021, all fillers (both for cosmetic and for medical purposes) are classified as class III risk medical devices. This means that all injectable products must be CE certified by a notified body if marketed after 26 May 2020. Thus, manufacturers required documentation including a device master record (technical documentation) and product clinical evaluation in accordance with MEDDEV 2.7/1 as well as an appropriate quality management system according to the Medical Devices Directive (MDD) ISO 13485. As regards injectable soft tissue fillers for cosmetic purposes, because of the absence of an intended medical purpose, they do not require a clinical efficacy investigation, but they are subject to a clinical evaluation regarding safety. Additionally, for materials of animal origin, such as collagen, manufacturers have to comply also with Regulation EU 722/2012.

### **9. Concluding Remarks**

Forerunner fillers were plagued by frequent unwanted side effects and serious complications (i.e., migration of injected filler, granulomatous inflammation, tissue necrosis, and hypersensitivity reactions). With the advancement of research, a new generation of fillers has been developed that have overcome some of the many existing earlier problems. The steps forward regarding safety and the refinement of injection techniques brought an exponential increase in and use of soft tissue filler products and procedures. This growth was fueled by the increased availability of new dermal filler products and by their improved safety profiles.

Injectable systems hold great promise in tissue engineering applications as they can potentially provide for an adequate temporal environment for the injured site regeneration, as well as delivering water soluble drugs, growth factors and cells for better outcomes. Thus, the injectable formulations must have both structural (i.e., filling role) and biological (i.e., pro-regenerative action) impermanent functions. In particular, the hydrogel should not only structurally support tissue regeneration but also stimulate its regeneration and be gradually digested and replaced by the newly synthetized tissue, resulting in a new functional tissue. The success of any injectable system is strongly determined by the framework the hydrogel provides. The 3D network should provide mechanical support compliant with the injured tissue, adequate pore size and interconnectivity to allow mass transport and regenerative processes, and eventually, must provide for the controlled release of bioactive molecules. In clinical setting, injectable materials hold the promise of being an effective minimally invasive treatment for mild-severe defects. The delivery of cells, bioactive factors, and support materials via an injectable system within the context of an endoscopic, arthroscopic, laparoscopic, or radiologically guided procedure is feasible and potentially successful. With the growing knowledge and technology in biomedical and materials sciences, the innovation of injectable biomaterials to fulfill unmet clinical needs is expected to thrive in the near future [14]. Indeed, a high number of bioactive injectable biomaterials have been developed and approved for clinical use.

Among them, multifunctional collagen products are effective in some clinical applications. However, there are some points to be clarified and obstacles to overcome in order to develop disease specific products. As the outcomes of research move toward clinical translation, the elucidation of the mechanisms of interactions between an injectable biomaterial and its surroundings is necessary to reach optimal material performance. However, the interaction between the host tissue and the material is unknown due to the lack of accurate and adequate in vivo evaluation. The scarcity of tools for the in vivo evaluation of injectable biomaterials has posed numerous difficulties in fully understanding injection consequences [14] but, nowadays, new advanced investigation techniques such as cone beam and micro computed X-ray tomography, immunohistochemistry, small-angle X-ray scattering, X-ray diffraction, and the more recent fluorescent labelling of abundant reactive entities, optical photothermal infrared microscopy and infrared atomic force microscopy, fluorescence lifetime imaging microscopy and Raman spectroscopy will allow us to overcome this issue and deeply understand the material's action mechanism over time [3]. These techniques will also allow us to tune the properties of injectable materials according to patient specific disease requirements and comorbidities in order to develop personalized therapies. Moreover, the deep in vivo investigation of the material-tissue interaction will allow us to overcome another important issue of injectable formulations, that is, the effectiveness of mass transport. Clinically available collagen injectables efficacy is hindered by the absence of nutrients necessary to support cell regenerative processes that could be responsible for delayed and deficient integration with the host tissue, especially in the case of large defect regions [68]. To overcome these limits, Alnojeidi et al. developed a new in situ cross-linkable injectable formulation of cross-linked bovine type I collagen, chondroitin sulfate and polyvinyl alcohol, that contains the optimum concertation of necessary amino acids, vitamins, and minerals required for cell growth and proliferation [68].

In addition, the high costs associated with the development and manufacture of medical-grade injectable biomaterials (i.e., basic and applied research on medical device design, raw material extraction, material properties assessment, sterile device production, package and storage condition assessment) or with the incorporation of therapeutic agents are another hindrance to be overcome [14]. Sensitivity analyses showed that surgery would be less costly and more successful than collagen injection if the postoperative length of hospital stay was reduced to 1 day or if the number of injections required to treat patients were more than two for treatment successes and more than four for treatment failures [186]. Endoscopic injection of collagen is effective in many cases, but its cost effectiveness depends on the number of re-injections required. In the treatment for vesicoureteral reflux single collagen injections were very effective and may effectively reduce health care management costs of about \$7544 per renal unit (collagen injection cost: \$1599, reimplantation cost: \$9144) [239]. In the treatment of the stress urinary incontinence, collagen injection is more cost effective than surgery if one application resolves the problem [123]. Instead, surgery (i.e., artificial genitourinary sphincter placement) is more cost effective than collagen injection when more than three collagen injections are required (collagen injection cost: \$4300–6021; artificial genitourinary sphincter placement \$11,933–15,400) [123,240]. In the case of aesthetic surgery, fillers would be less costly than surgical rhytidectomy (\$15,181) in cases of small facial area. In cases of large volume, the medical cost for surgery would be the lowest cost option among the other treatments over the course of several years [1].

Indeed, when developing a new injectable, materials factors such as product cost, scalability and maneuverability should be considered together with safety and quality profiles before proceeding with its pre-clinical and clinical evaluation. Many promising collagen-based materials have been designed and intensely investigated from the physical, chemical, mechanical, morphological and biological (both in vitro and in vivo) point of view but did not attain clinical translation. The consideration of the clinical potential of the material is nowadays mandatory to receive the regulation body approval besides expecting its clinical success [3]. This approach will reduce the tremendous discrepancy between the

huge quantity of academic research and the number of products that have been clinically translated [3].

Therefore, much research still needs to be carried out before minimally invasive strategies equal or surpass in terms of effectiveness the currently performed surgical procedures. However, the complete replacement of time-consuming and costly surgeries with injections does not seem to be so far away. In fact, even more collagen-based products are demonstrating their effectiveness in one or more sessions and in various injured body structures. Furthermore, actual preclinical and clinical research is not only confirming their assessed efficacy, but it is improving both formulations and injection techniques, as well as testing them for new, challenging, unresolved diseases.

In achieving this ultimate goal, the collaboration and transparency between researchers, clinicians, patients and companies has proved to be the only constructive way to successfully develop innovative and functional products capable of truly improving human health and making such treatments viable on a large-scale, accessible to the majority of the population and offering patients a long-term quality of life.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

### **References**


**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
